4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial
- Author
- [email protected] (Vinay Prasad, MD MPH)
- Published
- Sat 04 Jun 2022
- Episode Link
- https://soundcloud.com/plenarysession/462-shine-ibrutinib-br-vs-br-limitations-to-the-trial
Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint
No OS
Bad crossover
Lots to discuss here
I will be covering all the major ASCO papers on @PlenarySession
Subscribe to my substack https://vinayprasadmdmph.substack.com/
